Interferon-β-Induced Pulmonary Arterial Hypertension: Approach to Diagnosis and Clinical Monitoring

Overview

Journal JACC Case Rep

Specialty Cardiology & Vascular Diseases

Date 2021 Jul 28

PMID 34317680

Citations 3

Authors

Farhan Raza

Callyn Kozitza

Amy Chybowski

Kara N Goss

Theodore Berei

James Runo

Marlowe Eldridge

Naomi Chesler

Affiliations

Soon will be listed here.

Abstract

A 48-year-old woman who had been receiving long-term interferon-β for 8 years for multiple sclerosis developed drug-induced World Health Organization group I pulmonary arterial hypertension. Triple therapy for pulmonary arterial hypertension and suspension of interferon-β led to improvement from a high-risk to low-risk state and improvement in exercise hemodynamics, including vascular distensibility, and right ventricle-pulmonary artery coupling. ().

Citing Articles

Intestinal IFNα4 promotes 15-HETE diet-induced pulmonary hypertension.

Ruffenach G, Medzikovic L, Aryan L, Sun W, Lertpanit L, OConnor E Respir Res. 2024; 25(1):419.

PMID: 39609844 PMC: 11606228. DOI: 10.1186/s12931-024-03046-z.

IFNAR2 relevance in the clinical outcome of individuals with severe COVID-19.

Fricke-Galindo I, Martinez-Morales A, Chavez-Galan L, Ocana-Guzman R, Buendia-Roldan I, Perez-Rubio G Front Immunol. 2022; 13:949413.

PMID: 35967349 PMC: 9374460. DOI: 10.3389/fimmu.2022.949413.

Distinguishing exercise intolerance in early-stage pulmonary hypertension with invasive exercise hemodynamics: Rest V /VCO and ETCO identify pulmonary vascular disease.

Raza F, Dharmavaram N, Hess T, Dhingra R, Runo J, Chybowski A Clin Cardiol. 2022; 45(7):742-751.

PMID: 35419844 PMC: 9286332. DOI: 10.1002/clc.23831.

References

Savale L, Sattler C, Gunther S, Montani D, Chaumais M, Perrin S . Pulmonary arterial hypertension in patients treated with interferon. Eur Respir J. 2014; 44(6):1627-34. DOI: 10.1183/09031936.00057914. View

Badesch D, Raskob G, Elliott C, Krichman A, Farber H, Frost A . Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2009; 137(2):376-87. DOI: 10.1378/chest.09-1140. View

Bellofiore A, Vanderpool R, Brewis M, Peacock A, Chesler N . A novel single-beat approach to assess right ventricular systolic function. J Appl Physiol (1985). 2017; 124(2):283-290. PMC: 5867365. DOI: 10.1152/japplphysiol.00258.2017. View

Badiger R, Mitchell J, Gashaw H, Galloway-Phillipps N, Foser S, Tatsch F . Effect of different interferonα2 preparations on IP10 and ET-1 release from human lung cells. PLoS One. 2012; 7(10):e46779. PMC: 3466308. DOI: 10.1371/journal.pone.0046779. View

Malhotra R, Dhakal B, Eisman A, Pappagianopoulos P, Dress A, Weiner R . Pulmonary Vascular Distensibility Predicts Pulmonary Hypertension Severity, Exercise Capacity, and Survival in Heart Failure. Circ Heart Fail. 2016; 9(6). PMC: 4911900. DOI: 10.1161/CIRCHEARTFAILURE.115.003011. View

Tello K, Wan J, Dalmer A, Vanderpool R, Ghofrani H, Naeije R . Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension. Circ Cardiovasc Imaging. 2019; 12(9):e009047. PMC: 7099862. DOI: 10.1161/CIRCIMAGING.119.009047. View

Benza R, Gomberg-Maitland M, Miller D, Frost A, Frantz R, Foreman A . The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2011; 141(2):354-362. DOI: 10.1378/chest.11-0676. View

Savale L, Chaumais M, OConnell C, Humbert M, Sitbon O . Interferon-induced pulmonary hypertension: an update. Curr Opin Pulm Med. 2016; 22(5):415-20. DOI: 10.1097/MCP.0000000000000307. View

Vanderpool R, Pinsky M, Naeije R, Deible C, Kosaraju V, Bunner C . RV-pulmonary arterial coupling predicts outcome in patients referred for pulmonary hypertension. Heart. 2014; 101(1):37-43. PMC: 4268056. DOI: 10.1136/heartjnl-2014-306142. View

10.

Jonasch E, Haluska F . Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001; 6(1):34-55. DOI: 10.1634/theoncologist.6-1-34. View

11.

Singh I, Rahaghi F, Naeije R, Oliveira R, Vanderpool R, Waxman A . Dynamic right ventricular-pulmonary arterial uncoupling during maximum incremental exercise in exercise pulmonary hypertension and pulmonary arterial hypertension. Pulm Circ. 2019; 9(3):2045894019862435. PMC: 6643191. DOI: 10.1177/2045894019862435. View

12.

George P, Oliver E, Dorfmuller P, Dubois O, Reed D, Kirkby N . Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ Res. 2013; 114(4):677-88. PMC: 4006084. DOI: 10.1161/CIRCRESAHA.114.302221. View